Promising Results in Bowel Cancer Treatment Trial
A recent study has shown encouraging results for bowel cancer patients, with all participants remaining cancer-free nearly three years after testing an experimental treatment. Conducted by researchers at University College London and UCL Hospitals, the study highlights the potential benefits of using a short course of immunotherapy prior to surgery, which could outperform the typical treatment currently offered to some patients.
The trial examined 32 patients diagnosed with stage 2 or 3 bowel cancer. These individuals had tumors with a unique genetic marker known as MMR deficiency, which occurs in about 10% to 15% of bowel cancer cases. This genetic issue suggests a malfunction in the body’s DNA repair system, but it also presents an opportunity for immunotherapy drugs to effectively target the tumors.
Patients in the study received a drug called pembrolizumab for up to nine weeks before undergoing surgery, rather than following up surgery with conventional chemotherapy. Remarkably, data from the trial revealed that 59% of the patients had no cancer detected by the time of their surgery.
Even more impressive, follow-up data indicated that none of these patients experienced a recurrence of the disease over the span of 33 months, including those who had small amounts of cancer left post-surgery that remained dormant.
Dr. Kai-Keen Shiu, a leading medical oncologist at UCLH and an associate professor at UCL, expressed optimism about the findings. “No recurrence of cancer after nearly three years is very encouraging and reinforces our belief that pembrolizumab is a safe and effective treatment for high-risk bowel cancer patients,” he stated.
Typically, for patients with the genetic profile involved in this study, traditional treatment methods result in about 25% experiencing a cancer return within three years.
To monitor treatment effectiveness, the research team employed personalized blood tests that detect tiny fragments of tumor DNA in the bloodstream. This method helps doctors gauge whether the treatment is working before the surgical procedure.
Yanrong Jiang, a clinical PhD student at the UCL Cancer Institute, noted, “When we saw the tumor DNA disappear from the blood, it made it more likely that there was no cancer remaining, aligning with the long-term outcomes we’re observing now.”
However, researchers did caution that the study was limited by its small sample size and focus on a specific genetic subset, which means the results may not be applicable to all bowel cancer patients.
Looking ahead, the researchers aim to continue following these patients to ensure that the cancer does not return. They are also excited about the future potential of personalized medicine. Dr. Shiu added, “Using personalized blood tests and immune profiling, we may be able to identify which patients will benefit from this treatment and tailor their therapy accordingly.”
The promising results were shared at the American Association for Cancer Research (AACR) Annual Meeting, held in San Diego last month, paving the way for new hope in bowel cancer treatment.
